# Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies

> **NCT04519710** · NA · COMPLETED · sponsor: **Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida** · enrollment: 60 (actual)

## Conditions studied

- HBV

## Interventions

- **BIOLOGICAL:** o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B

## Key facts

- **NCT ID:** NCT04519710
- **Lead sponsor:** Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-15
- **Primary completion:** 2021-09-15
- **Final completion:** 2023-10-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04519710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04519710, "Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04519710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*